Results showed that tissues expressing high levels of ZBTB46 were associated with an upregulated NEPC-responsive signature in the prostate cancer dataset by a gene set enrichment analysis (GSEA)25 (Fig. 1a). This evidence concerns the gene ZBTB46 and prostate carcinoma.